WO2003063771A3 - N4-acylcytosine nucleosides for treatment of viral iinfections - Google Patents

N4-acylcytosine nucleosides for treatment of viral iinfections Download PDF

Info

Publication number
WO2003063771A3
WO2003063771A3 PCT/US2002/040081 US0240081W WO03063771A3 WO 2003063771 A3 WO2003063771 A3 WO 2003063771A3 US 0240081 W US0240081 W US 0240081W WO 03063771 A3 WO03063771 A3 WO 03063771A3
Authority
WO
WIPO (PCT)
Prior art keywords
iinfections
acylcytosine
nucleosides
viral
treatment
Prior art date
Application number
PCT/US2002/040081
Other languages
French (fr)
Other versions
WO2003063771A2 (en
Inventor
Kyoichi A Watanabe
Junxing Shi
Michael J Otto
Original Assignee
Pharmasset Ltd
Kyoichi A Watanabe
Junxing Shi
Michael J Otto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasset Ltd, Kyoichi A Watanabe, Junxing Shi, Michael J Otto filed Critical Pharmasset Ltd
Priority to BR0214944-3A priority Critical patent/BR0214944A/en
Priority to JP2003563467A priority patent/JP2005519916A/en
Priority to KR1020047009263A priority patent/KR100978904B1/en
Priority to CA2470255A priority patent/CA2470255C/en
Priority to AU2002365234A priority patent/AU2002365234B2/en
Priority to EP02804833A priority patent/EP1569652A4/en
Priority to MXPA04005779A priority patent/MXPA04005779A/en
Publication of WO2003063771A2 publication Critical patent/WO2003063771A2/en
Publication of WO2003063771A3 publication Critical patent/WO2003063771A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Abstract

The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animals hosts, comprising the administration of N4-acyl-2',3'-dideoxy-5-flluorocytidine or N4-acyl-2',3'-didehydro-2',3' dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.
PCT/US2002/040081 2001-12-14 2002-12-13 N4-acylcytosine nucleosides for treatment of viral iinfections WO2003063771A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR0214944-3A BR0214944A (en) 2001-12-14 2002-12-13 N4-Acylcytosine Nucleosides for the Treatment of Viral Infections
JP2003563467A JP2005519916A (en) 2001-12-14 2002-12-13 N4-acylcytosine nucleosides for the treatment of viral infection
KR1020047009263A KR100978904B1 (en) 2001-12-14 2002-12-13 N4-Acylcytosine nucleosides for treatment of viral infections
CA2470255A CA2470255C (en) 2001-12-14 2002-12-13 N4-acylcytosine nucleosides for treatment of viral infections
AU2002365234A AU2002365234B2 (en) 2001-12-14 2002-12-13 N4-acylcytosine nucleosides for treatment of viral infections
EP02804833A EP1569652A4 (en) 2001-12-14 2002-12-13 N sp 4 /sp-acylcytosine nucleosides for treatment of viral iinfections
MXPA04005779A MXPA04005779A (en) 2001-12-14 2002-12-13 N4.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34155501P 2001-12-14 2001-12-14
US60/341,555 2001-12-14

Publications (2)

Publication Number Publication Date
WO2003063771A2 WO2003063771A2 (en) 2003-08-07
WO2003063771A3 true WO2003063771A3 (en) 2005-07-07

Family

ID=23338072

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2002/040081 WO2003063771A2 (en) 2001-12-14 2002-12-13 N4-acylcytosine nucleosides for treatment of viral iinfections
PCT/US2002/040090 WO2003051306A2 (en) 2001-12-14 2002-12-16 N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2002/040090 WO2003051306A2 (en) 2001-12-14 2002-12-16 N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections

Country Status (10)

Country Link
US (6) US7105527B2 (en)
EP (1) EP1569652A4 (en)
JP (1) JP2005519916A (en)
KR (1) KR100978904B1 (en)
CN (1) CN100560073C (en)
AU (2) AU2002365234B2 (en)
BR (1) BR0214944A (en)
CA (1) CA2470255C (en)
MX (1) MXPA04005779A (en)
WO (2) WO2003063771A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790228B2 (en) * 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
EP1284741B1 (en) 2000-04-13 2008-11-19 Pharmasset, Inc. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CN101099745A (en) * 2000-05-26 2008-01-09 艾登尼科斯（开曼）有限公司 Methods and compositions for treating flaviviruses and pestiviruses
CN100560073C (en) * 2001-12-14 2009-11-18 法玛塞特公司 The N that is used for the treatment of viral infection 4-acyl group cytidine
CN101172993A (en) * 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
RS113904A (en) * 2002-06-28 2007-02-05 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
EP1545545A4 (en) 2002-08-01 2008-09-03 Pharmasset Inc COMPOUNDS WITH THE BICYCLO 4.2.1 NONANE SYSTEM FOR THE TREATMENT OF i FLAVIVIRIDAE /i INFECTIONS
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
US7598373B2 (en) * 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
CA2425031A1 (en) * 2003-04-01 2004-10-01 Smithkline Beecham Corporation Pharmaceutical compositions
KR100883703B1 (en) * 2003-05-30 2009-02-12 파마셋 인코포레이티드 Modified fluorinated nucleoside analogues
US7741334B2 (en) * 2004-04-01 2010-06-22 Achillion Pharmaceuticals, Inc. Low dose therapy for treating viral infections
CN101023094B (en) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
SI3109244T1 (en) 2004-09-14 2019-06-28 Gilead Pharmasset Llc Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
EP1802315A2 (en) * 2004-10-19 2007-07-04 Achillion Pharmaceuticals, Inc. Combination therapy for treating viral infections
US7968703B2 (en) * 2005-03-07 2011-06-28 Shire Canada Inc. Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof
CA2634749C (en) * 2005-12-23 2014-08-19 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2671888A1 (en) 2008-12-23 2013-12-11 Gilead Pharmasset LLC 3',5'-cyclic nucleoside phosphate analogues
NZ617066A (en) 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
PL3290428T3 (en) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
CL2011000716A1 (en) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Crystalline forms 1 6 of (s) -isopropyl-2 - (((s) - (((2r.3r.4r.5r) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2h) -yl) -4-fluoro-3-hydroxy-4-methyl tetrahydrofuran-2-yl) methoxy) (phenoxy) phosphoryl) amino) propanoate; pharmaceutical composition and combination; and its use to treat a hepatitis c virus infection.
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
HUE036588T2 (en) 2011-09-16 2018-07-30 Gilead Pharmasset Llc Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN103242400B (en) * 2012-02-08 2016-06-08 河南师范大学 There is 5-substituted pyrimidines nucleoside-thiazolidhybrid hybrid and its preparation method of HIV (human immunodeficiency virus)-resistant activity
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP4005560A1 (en) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EP3265102A4 (en) 2015-03-06 2018-12-05 ATEA Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
KR20190043602A (en) 2016-09-07 2019-04-26 아테아 파마슈티컬즈, 인크. 2'-substituted-N6-substituted purine nucleotides for the treatment of RNA viruses
SG11201906163TA (en) 2017-02-01 2019-08-27 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
CN112351799A (en) 2018-04-10 2021-02-09 阿堤亚制药公司 Treatment of HCV infected patients with cirrhosis
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043691A1 (en) * 1998-02-25 1999-09-02 Emory University 2'-fluoronucleosides

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US13660A (en) * 1855-10-09 Improvements
US3309359A (en) * 1965-10-22 1967-03-14 Hoffmann La Roche N-mono-acyl-5-fluorocytosine derivatives and process
NL8202626A (en) 1982-06-29 1984-01-16 Stichting Rega V Z W DERIVATIVES OF 9- (2-HYDROXYETHOXYMETHYL) GUANINE.
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
ZA886890B (en) * 1987-10-09 1989-05-30 Hoffmann La Roche Novel dideoxycytidine derivatives
US6350753B1 (en) * 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
NL8901258A (en) 1989-05-19 1990-12-17 Stichting Rega V Z W New 5-halo-2'-3'-di:deoxy-cytidine derivs. - useful as anti-retro-viral agents, esp. for treating HIV infections
DD293498A5 (en) 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De METHOD FOR PRODUCING A MEDIUM FOR THE TREATMENT OR PROPHYLAXIS OF HEPATITE INFECTIONS IN HUMANS AND ANIMALS
JPH05310777A (en) 1992-05-14 1993-11-22 Yoshitomi Pharmaceut Ind Ltd 2'-deoxy-2'-methylidynecytidine compound
TW254946B (en) * 1992-12-18 1995-08-21 Hoffmann La Roche
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
GB9525606D0 (en) * 1995-12-14 1996-02-14 Iaf Biochem Int Method and compositions for the synthesis of dioxolane nucleosides with › - configuration
AU4988697A (en) * 1996-10-24 1998-05-15 Vion Pharmaceuticals, Inc. Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents
AU1412299A (en) * 1997-11-25 1999-06-15 Protarga, Inc. Nucleoside analog compositions and uses thereof
CN100376570C (en) * 2000-10-13 2008-03-26 希拉生物化学股份有限公司 Dioxolane analogs for improved inter-cellular delivery
KR20090089922A (en) * 2000-10-18 2009-08-24 파마셋 인코포레이티드 Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
CN100560073C (en) * 2001-12-14 2009-11-18 法玛塞特公司 The N that is used for the treatment of viral infection 4-acyl group cytidine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043691A1 (en) * 1998-02-25 1999-09-02 Emory University 2'-fluoronucleosides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1569652A4 *

Also Published As

Publication number Publication date
USRE42015E1 (en) 2010-12-28
JP2005519916A (en) 2005-07-07
US20070078080A1 (en) 2007-04-05
US8114997B2 (en) 2012-02-14
WO2003051306A3 (en) 2003-12-18
US20040214844A1 (en) 2004-10-28
CA2470255A1 (en) 2003-08-07
US20030176319A1 (en) 2003-09-18
EP1569652A4 (en) 2008-07-02
AU2002364730A8 (en) 2003-06-30
KR100978904B1 (en) 2010-08-31
WO2003063771A2 (en) 2003-08-07
CN1617726A (en) 2005-05-18
CA2470255C (en) 2012-01-17
US7105527B2 (en) 2006-09-12
AU2002365234B2 (en) 2009-01-29
EP1569652A2 (en) 2005-09-07
AU2002364730A1 (en) 2003-06-30
CN100560073C (en) 2009-11-18
MXPA04005779A (en) 2005-05-16
BR0214944A (en) 2005-06-07
KR20040094398A (en) 2004-11-09
US20090176730A1 (en) 2009-07-09
US6908924B2 (en) 2005-06-21
WO2003051306A2 (en) 2003-06-26
US20120202766A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
WO2003063771A3 (en) N4-acylcytosine nucleosides for treatment of viral iinfections
WO2001090121A3 (en) Methods and compositions for treating hepatitis c virus
WO2003026589A3 (en) Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
WO2004046159A8 (en) Antiviral nucleoside derivatives
WO2002100415A3 (en) 4'-substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
IL153078A0 (en) Methods for treating hepatitis delta virus infection with beta-l-2' deoxy nucleosides
EP1808434A3 (en) Use of 5-fluoro-2'-deoxy-3'-thiacytidine fo the treatment of hepatitis B
CA2445744A1 (en) Antiviral nucleoside derivatives
MY128463A (en) 4' substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
WO1998001144A2 (en) Antiviral agents from plant extracts and use for treatment of viral infections
CA2271622A1 (en) Antiviral agents from plant extracts and use for treatment of viral infections
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
DK92788A (en) USE OF 3'-DEOXY-3'-FLUORUANOSIDES FOR THE PREPARATION OF MEDICINAL PRODUCTS AGAINST RETROVIRA
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
MY127808A (en) Use of dideoxy nucleoside analogues in the treatment of viral infections
WO2006045616A3 (en) β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES
WO2005097618A3 (en) Low dose therapy for treating viral infections
CA2198010A1 (en) 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-2-cyclopentene-1-methanol succinate as antiviral agent
WO2004043402A3 (en) Modified nucleosides as antiviral agents
RU93058325A (en) APPLICATION OF 1,3-OXATHIOLANE DERIVATIVES FOR PRODUCTION OF MEDICINES FOR THE TREATMENT OR PREVENTION OF HEPATITIS B VIRAL INFECTION, APPLICATION OF 1,3 - OXATHYOLANE DERIVATIVES FOR THE TREATMENT OF HEPATITIS
MY137298A (en) Therapeutic nucleosides
WO2004013298A3 (en) 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections
WO2000043014A3 (en) Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections
WO2002009677A3 (en) Method to treat infectious diseases and/or to enhance antimicrobial efficacy of drugs
MY113560A (en) Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/005779

Country of ref document: MX

Ref document number: 2003563467

Country of ref document: JP

Ref document number: 2470255

Country of ref document: CA

Ref document number: 1020047009263

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002365234

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002804833

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20028278402

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002804833

Country of ref document: EP